Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by ORIC Pharmaceuticals

< Previous 1 2 3 Next >
ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Announces $85 Million Private Placement Financing
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals to Participate in the Jefferies Healthcare Conference
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals to Participate in the Oppenheimer 33rd Annual Healthcare Conference
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual Meeting
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals to Present at the Jefferies London Healthcare Conference
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple Myeloma at the 64th American Society of Hematology (ASH) Annual Meeting
From ORIC Pharmaceuticals
Via GlobeNewswire
Tickers ORIC
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.